By CNBC-TV18's research analyst, Archi Damania

Ranbaxy Labs is to announce its Q1CY08 numbers. According to CNBC-TV18 estimates, the company is expected to post 9% growth in its consolidated net profit of Rs 139 crore as against Rs 127.60 crore YoY.

Net sales is seen going up 11% at Rs 1731 crore versus Rs 1553.50 crore. Operating profit is likely to go up at Rs 271.80 crore from Rs 190.8 crore. OPM is expected to be at 15.5% versus 12.06%.

Factors to watch

• Absence of any blockbuster product in US will keep overall growth modest
• Sales  growth on account of growth in branded formulations in export markets like Latin America and middle east ie. the semi regulated markets
• Will report Lower other income mainly due to translation losses on FCCB (earlier due to rupee appreciation was reporting gains on MTM FCCB)
• EBIDTA margin is likely to increase due to low base and favorable sales mix and increased branded formulation exports